What does this research mean for the field?

The Solaris self-expanding covered stent provides high technical success, excellent 12-month patency, and significant symptom improvement in patients with iliac artery occlusive disease, including those with complex TASC C-D lesions. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the short-term clinical and patency outcomes of the Solaris self-expanding covered stent in patients with iliac artery occlusive disease.

September 15, 2026Diagnostic and Interventional RadiologyOpen Access

Short-term outcomes of Solaris self-expanding covered stent in iliac artery occlusive disease: a single-center retrospective cohort

View Full Paper

Ask AI

Bookmark

Authors

HTHalil TekdemirBilkent University MBMuhammed Said BeşlerIstanbul Medeniyet University EAEda Sener AlcınBilkent University

Discussion

Member takes

Overview

Retrospective cohort study demonstrates high patency and symptom relief with Solaris covered stents in iliac artery occlusive disease, suggesting an effective endovascular option for complex lesions.

Key Points

To evaluate the short-term clinical and patency outcomes of the Solaris self-expanding covered stent in patients with iliac artery occlusive disease.
Single-center retrospective study of 99 consecutive patients (140 iliac arteries, 55.7% TASC C-D lesions) treated with the Solaris self-expanding covered stent between October 2023 and December 2025.
Evaluated technical success, symptom improvement via Rutherford category, and primary patency using Kaplan-Meier analysis over a median follow-up of 278 days (range, 32–576 days).
Technical success was 100% across 184 implanted stents, with estimated Kaplan-Meier primary patency reaching 100% at 6 months and 97.6% at 12 months.
Primary patency did not differ significantly between TASC A-B and TASC C-D lesions (log-rank P = 0.206).
Symptom improvement by at least one Rutherford category was achieved in 96.0% of patients (80.8% reached Rutherford category 0), with no procedure-related deaths.

Cite This Study

Tekdemir et al. (2026) studied this question.

synapsesocial.com/papers/6aa913d99013453be30a203e https://doi.org/10.4274/dir.2026.264163

View Full Paper

Ask AI

Bookmark

September 15, 2026Diagnostic and Interventional RadiologyOpen Access

Short-term outcomes of Solaris self-expanding covered stent in iliac artery occlusive disease: a single-center retrospective cohort

View Full Paper

Ask AI

Bookmark

Authors

HTHalil TekdemirBilkent University MBMuhammed Said BeşlerIstanbul Medeniyet University EAEda Sener AlcınBilkent University

Discussion

Member takes

Overview

Retrospective cohort study demonstrates high patency and symptom relief with Solaris covered stents in iliac artery occlusive disease, suggesting an effective endovascular option for complex lesions.

Key Points

To evaluate the short-term clinical and patency outcomes of the Solaris self-expanding covered stent in patients with iliac artery occlusive disease.
Single-center retrospective study of 99 consecutive patients (140 iliac arteries, 55.7% TASC C-D lesions) treated with the Solaris self-expanding covered stent between October 2023 and December 2025.
Evaluated technical success, symptom improvement via Rutherford category, and primary patency using Kaplan-Meier analysis over a median follow-up of 278 days (range, 32–576 days).
Technical success was 100% across 184 implanted stents, with estimated Kaplan-Meier primary patency reaching 100% at 6 months and 97.6% at 12 months.
Primary patency did not differ significantly between TASC A-B and TASC C-D lesions (log-rank P = 0.206).
Symptom improvement by at least one Rutherford category was achieved in 96.0% of patients (80.8% reached Rutherford category 0), with no procedure-related deaths.

Cite This Study

Tekdemir et al. (2026) studied this question.

synapsesocial.com/papers/6aa913d99013453be30a203e https://doi.org/10.4274/dir.2026.264163

View Full Paper

Ask AI

Bookmark